Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

Abstract This open‐label, phase I dose‐finding study evaluated the gonadotropin‐releasing hormone antagonist, TAK‐385, in Japanese patients with nonmetastatic prostate cancer. In a two‐part design, patients received daily oral TAK‐385 at doses of 320 (loading, day 1)/80 (maintenance, day 2 and there...

Full description

Bibliographic Details
Main Authors: Hiroyoshi Suzuki, Hiroji Uemura, Atsushi Mizokami, Narihiko Hayashi, Yasuhide Miyoshi, Satoshi Nagamori, Yutaka Enomoto, Hideyuki Akaza, Takayuki Asato, Tadayuki Kitagawa, Kazuhiro Suzuki
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Medicine
Subjects:
hormone therapy
prostate cancer
Online Access:https://doi.org/10.1002/cam4.2442

Internet

https://doi.org/10.1002/cam4.2442

Similar Items